VanEck Biotech ETF (NASDAQ:BBH) Reaches New 1-Year High – Should You Buy?

VanEck Biotech ETF (NASDAQ:BBH)’s stock price reached a new 52-week high on Thursday. The stock traded as high as $247.83 and last traded at $247.7640, with a volume of 5,352 shares. The stock had previously closed at $241.07.

VanEck Biotech ETF Stock Down 2.1%

The company has a 50 day moving average price of $236.33 and a 200-day moving average price of $208.66.

Institutional Investors Weigh In On VanEck Biotech ETF

Institutional investors have recently added to or reduced their stakes in the business. Coastline Trust Co acquired a new position in VanEck Biotech ETF in the 3rd quarter valued at approximately $46,000. CoreCap Advisors LLC acquired a new position in shares of VanEck Biotech ETF during the third quarter worth $46,000. First PREMIER Bank acquired a new position in shares of VanEck Biotech ETF during the second quarter worth $91,000. Farther Finance Advisors LLC bought a new stake in shares of VanEck Biotech ETF in the third quarter worth $123,000. Finally, BigSur Wealth Management LLC bought a new stake in shares of VanEck Biotech ETF in the third quarter worth $126,000. 32.05% of the stock is owned by institutional investors.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.